Crane Venture Partners

Crane Venture Partners is a London-based early-stage firm with a tight thesis: intelligent enterprise software, often technical and infrastructure-flavoured, sold to other enterprises. The team is one of the more focused seed investors in Europe on AI-native and data-native B2B startups, and that lens makes them a relevant name for founders building developer tools, platforms, or vertical AI applications that touch healthcare workflows or life sciences research.

The thesis centres on intelligent applications, data infrastructure, dev tools, and vertical AI, with healthcare appearing where AI/ML or Health IT software meets real enterprise buyers. Crane is not a generalist digital health fund; consumer health, marketplaces, and services-heavy models are usually a poor fit. Where they engage on healthcare is when the company looks more like a software business than a clinical business: defensible product, technical moat, repeatable sales motion, and a CTO who can hold their own in a deep technical conversation.

Check sizes typically range from one to five million dollars at pre-seed and seed, with Crane comfortable leading rounds, taking a board seat, and acting as a long-term seed partner through Series A. They follow on selectively. Geography is European with a strong UK bias; US founders who fit the thesis are looked at, but the centre of gravity is London, Berlin, Stockholm, and surrounding hubs.

The team is partner-led and small enough that diligence and decision-making are concentrated. Crane also runs an active community programme and content, which means founders who engage with the firm before they raise tend to be on the radar before formal pitch decks circulate. Portfolio support is concrete: hiring, US expansion, Series A preparation, and connections into the broader European enterprise software ecosystem.

The right way to approach is through a warm introduction from a Crane portfolio CEO, a respected angel or operator in the European AI scene, or by engaging credibly with the firm’s content and events first. When you reach out, bring a sharp narrative on the technical wedge, the data moat, and the buyer; healthcare-flavoured pitches that lead with model novelty without explaining who buys and why will not get far. The right moment is when you have a working product, early design partners, and a credible plan to use seed capital to convert design partners into paid customers. Founders pre-product with an idea but no team or working software should wait; founders ready to raise a focused seed with two to four million dollars to spend on the next eighteen months are squarely in scope. Crane is a serious, technically literate seed lead for the right kind of company, and a clear pass for everything else.